Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A DOUBLE-BLIND COMPARISON OF SERTRALINE AND IMIPRAMINE IN OUTPATIENTSWITH MAJOR DEPRESSION - ACUTE (8 WEEKS) AND CONTINUATION (16 WEEKS) TREATMENT
Autore:
FOURNIER JP; LANE RM; CHOUINARD G; WATSON DB; AMIN M; REMICK RA; THORPE LU;
Indirizzi:
PFIZER INC,235 E 42ND ST NEW YORK NY 10017 PFIZER INC NEW YORK NY 10017 PSYCHIAT SERV ST FOY PQ G1V 4G2 CANADA INST ALLAN MEM MONTREAL PQ CANADA VANCOUVER GEN HOSP VANCOUVER BC CANADA LAKESHORE GEN HOSP POINTE CLAIRE PQ CANADA UBC,HLTH SCI CTR HOSP VANCOUVER BC CANADA UNIV SASKATCHEWAN HOSP SASKATOON SK S7N 0W8 CANADA
Titolo Testata:
Human psychopharmacology
fascicolo: 3, volume: 12, anno: 1997,
pagine: 203 - 215
SICI:
0885-6222(1997)12:3<203:ADCOSA>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
OBSESSIVE-COMPULSIVE-DISORDER; SEROTONIN REUPTAKE; GENERAL-PRACTICE; PLACEBO; EFFICACY; AMITRIPTYLINE; METAANALYSIS; FLUOXETINE; INHIBITORS;
Keywords:
SERTRALINE; IMIPRAMINE; SELECTIVE SEROTONIN REUPTAKE INHIBITOR; ANTIDEPRESSANT; MAJOR DEPRESSION; CONTINUATION TREATMENT;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
39
Recensione:
Indirizzi per estratti:
Citazione:
J.P. Fournier et al., "A DOUBLE-BLIND COMPARISON OF SERTRALINE AND IMIPRAMINE IN OUTPATIENTSWITH MAJOR DEPRESSION - ACUTE (8 WEEKS) AND CONTINUATION (16 WEEKS) TREATMENT", Human psychopharmacology, 12(3), 1997, pp. 203-215

Abstract

In a double-blind multicentre trial in patients with major depression, the efficacy and the tolerability of sertraline were compared to those of imipramine, during an 8-week acute treatment phase followed by a16-week continuation treatment phase in treatment responders. A totalof 104 patients who met DSM-III-R criteria for major depression, HAM-D 17-item greater than or equal to 18 and Raskin Depression score > Covi Anxiety score, were randomized to receive either sertraline or imipramine. The initial daily dosage of 50 mg of sertraline or imipramine was rapidly titrated upwards in increments of 50 mg/day at weekly intervals, tolerability permitting, to a maximum of 200 mg/day by the fourth week. Eighty-eight patients completed at least 3 weeks of treatmentand were included in the efficacy evaluable population. Both treatment groups demonstrated similar improvements on depression and anxiety rating scales during acute treatment, however, sertraline demonstrated significantly more improvement relative to imipramine on the HAM-D andCovi Anxiety scales after 1 week of treatment. Sertraline was more effective (HAM-D 17-item, CGI-S, SCL-56 Total score, SCL-56 Depression score, Covi Anxiety score) than imipramine in reducing depressive symptoms at the end of 24 weeks of treatment. There were significant improvements in all rating scales at week 24 relative to week 8 in the sertraline group but not in the imipramine group. The SCL-56 Total score, SCL-56 Depression score, Raskin Depression score and Covi Anxiety scoreat week 24 relative to week 8 showed significantly greater improvement in the sertraline group compared to the imipramine group. Imipraminewas associated with a significantly higher incidence of dry mouth, sweating, constipation, palpitations, and a significantly higher heart rate and blood pressure. Sertraline was associated with a significantlyhigher incidence of diarrhoea/loose stools and insomnia. This study demonstrated a faster onset of therapeutic effect for sertraline relative to imipramine, reflecting the initiation of sertraline in a therapeutic dose of 50 mg/day and the need for gradual titration of imipramine to a therapeutic dose, at the beginning of treatment. Although efficacy was similar in both treatment groups at the end of the 8 weeks of acute therapy, sertraline-treated patients continued to manifest gradual improvements in depressive and anxiety symptoms during the 16 weeksof continuation therapy such that sertraline-treated patients were significantly more improved at the end of 24 weeks of therapy. (C) 1997 by John Wiley & Sons, Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/09/20 alle ore 03:29:57